Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN22044 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Intravenous (IV) Cohorts | EXPERIMENTAL | - |
| Subcutaneous (SC) Cohorts | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| REGN22044 | DRUG | Administered per the protocol |
| Placebo | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1\. Is judged by the investigator to be in good health as described in the protocol Key Exclusion Criteria: 1. History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease, a...
REGN22044 is an investigational small molecule being developed by Regeneron Pharmaceuticals, Inc. (REGN). It is currently in Phase 1 clinical development for healthy volunteers. The drug is being studied in a first-in-human trial to assess its safety, tolerability, and pharmacokinetics.
REGN22044 is being studied in healthy volunteers as part of a Phase 1 clinical trial. The primary purpose is to evaluate the safety, tolerability, and pharmacokinetics of a single dose. It is not yet approved for any medical condition and remains in early-stage clinical development.
REGN22044 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker REGN. The company is conducting a first-in-human study of this investigational small molecule in healthy adults.
REGN22044 is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. It is currently being evaluated in a first-in-human study to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
REGN22044 is being studied in a Phase 1 clinical trial with the identifier NCT07526116. This first-in-human study is assessing the safety, tolerability, and pharmacokinetics of a single dose of REGN22044 in healthy adults. The trial is recruiting participants in Belgium and aims to enroll 88 individuals.
REGN22044 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The ongoing trial is designed to evaluate its safety, tolerability, and pharmacokinetics in healthy volunteers, and regulatory approval has not been granted.